TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03030170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDO GIA X-tra Thick reload with Tri Staple Technology
Description: Suture of the pancreas by normal stapling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology
Description: Suture of the pancreas by reinforced stapling
Study: NCT00622453

Intervention type: OTHER
Intervention: Screening
Description: Electrocardiography Blood Test
Study: NCT03569657

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A positive psychology workshop
Description: Group workshop
Study: NCT00876928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: liquid vitamin D3 dissolved in medium chain triglyceride once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: medium chain triglyceride given once per week
Study: NCT03133754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DP-PEEP
Description: PEEP titration trial for the lowest DP after the alveolar recruitment maneuver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM-5
Description: Fixed standard PEEP after the alveolar recruitment maneuver
Study: NCT00518791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Care
Description: A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No altered organisation of care
Study: NCT00044538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY59-8862 (Cytotoxic Taxane)
Description: Intravenous dose over 60 minutes every 3 weeks
Study: NCT02245672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via the CRC749 and Diskus devices
Study: NCT00947557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutogliptin
Description: Dutogliptin oral administration once daily on background of glimepiride with or without metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration once daily on background of glimepiride with or without metformin
Study: NCT03924739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated integrated care model for AF
Description: Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
Study: NCT04648735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: driving evaluation and practice
Description: The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: driving evaluation and practice
Description: The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc.
Study: NCT01657955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Study: NCT03975738

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments

Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments
Study: NCT04012996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prodisc C SK and/or Vivo
Description: Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobi-C Cervical Disc
Description: Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
Study: NCT04398420

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVERP
Description: Transurethral Vapor Enucleation Resection of the prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TURis
Description: Transurethral Vapor Enucleation Resection of the prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: Transurethral Vapor Enucleation Resection of the prostate
Study: NCT03613441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Description: Please refer to arm description
Study: NCT01894633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total brain radiotherapy
Description: 30 Gy in 10 daily fractions from Monday to Friday

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Total brain radiotherapy
Description: 30 Gy in 10 daily fractions from Monday to Friday
Study: NCT01305525

Intervention type: DEVICE
Intervention: St. Jude Medical Spinal Cord Stimulation Systems
Description: Spinal cord stimulation
Study: NCT01097785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg, P.O.,daily for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 30 days
Study: NCT04357860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
Description: Best available treatment up to 14 days plus Sarilumab 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]
Description: Best available treatment up to 14 days plus Sarilumab 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available treatment
Description: Best available treatment up to 14 days
Study: NCT03125525

Intervention type: DEVICE
Intervention: Cefaly device
Description: Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
Study: NCT00728715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-formoterol single inhaler
Description: High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide-formoterol single inhaler
Description: High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of budesonide
Description: 1600 mcg/d of budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of budesonide
Description: 1600 mcg/d of budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: medium dose of budesonide-formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: High Dose Inhaled Budesonide
Study: NCT02898844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Diet Condition
Description: One roommate dieted and the other ate normally.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Diet Condition
Description: Both roommates dieted.
Study: NCT02358382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH Stat
Description: pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
Study: NCT00639912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
Study: NCT02562495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT Scan and ultrasonography
Description: Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
Study: NCT04581889

Intervention type: OTHER
Intervention: Diagnostic test
Description: Presence of antibodies in saliva
Study: NCT04012138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.
Study: NCT00837551

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
Study: NCT02558686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Detuned Ultrasound
Description: Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals will not perform any action after the application of trigger point dry needling
Study: NCT00938470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT04162340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4 CAR T cells
Description: CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT01095263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: 130Hz, 90us pulsewidth, 4V Amplitude

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: 130Hz, 90us pulsewidth, 4V Amplitude

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Stimulation (Sham)
Description: 130Hz, 90us pulsewidth, 0V Amplitude

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Stimulation (Sham)
Description: 130Hz, 90us pulsewidth, 0V Amplitude
Study: NCT03607539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum
Description: Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
Study: NCT03641612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one shape
Description: canal fluid sample before and after root canal instrumentation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: protaper next
Description: canal fluid sample before and after root canal instrumentation
Study: NCT00582868

Intervention type: DEVICE
Intervention: Licox Brain Oxygen Monitor
Description: use of data from brain oxygen monitor for analysis

Intervention type: OTHER
Intervention: CSF
Description: analysis of CSF for cleaved tau protein

Intervention type: OTHER
Intervention: Whole blood
Description: Analysis of whole blood for cleaved-tau protein
Study: NCT04119258

Intervention type: BEHAVIORAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy including both behavioral and cognitive interventions.
Study: NCT00675090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: GSK239512 oral tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match once a day
Study: NCT04953715

Intervention type: OTHER
Intervention: collection of body microbioma
Description: A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
Study: NCT01703351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: (n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 500mcg + acupan 160mg + nasea 0.6mg
Description: (n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
Study: NCT00599885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: telmisartan 40-80mg once per day for 8 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: valsartan 80-160mg once per day for 8 months
Study: NCT00884494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion to assess effects on insulin sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion to assess effects on insulin sensitivity
Study: NCT01122251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Valsartan
Description: L10/V80, L20/V80, L10/V160, L20/V160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine or Valsartan
Description: L10, L20, V80, V160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Lercanidipine and Valsartan
Study: NCT01284686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subthalamo-cortical loops stimulation in a one-sided and bipolar way
Description: Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
Study: NCT02546518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moniri Otovent
Description: Please see Arm Description.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tube in the ear drum
Description: Insertion of tympanostomy tube/Grommet in the ear drums.
Study: NCT00565188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate
Description: Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
Study: NCT02784756

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantiferon-CMV assay